Free Trial

Edesa Biotech (EDSA) Stock Price, News & Analysis

$5.42
+0.31 (+6.07%)
(As of 07/26/2024 ET)
Today's Range
$5.23
$5.59
50-Day Range
$4.15
$5.42
52-Week Range
$2.46
$8.33
Volume
10,436 shs
Average Volume
7,022 shs
Market Capitalization
$17.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.00

Edesa Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
619.6% Upside
$39.00 Price Target
Short Interest
Healthy
0.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.19) to ($1.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

Medical Sector

405th out of 936 stocks

Pharmaceutical Preparations Industry

188th out of 436 stocks

EDSA stock logo

About Edesa Biotech Stock (NASDAQ:EDSA)

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

EDSA Stock Price History

EDSA Stock News Headlines

Alex's "Next Magnificent Seven" Stocks
Today Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.
EDSA: Development of EB05 in ARDS Continues…
Edesa Biotech Inc (EDSA)
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
Alex's "Next Magnificent Seven" Stocks
Today Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.
Edesa Biotech Reports Fiscal Year 2023 Results
Edesa Biotech Inc EDSA
See More Headlines
Receive EDSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edesa Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/10/2024
Today
7/27/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EDSA
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.00
High Stock Price Target
$57.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+619.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-8,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.34 per share

Miscellaneous

Free Float
2,412,000
Market Cap
$17.45 million
Optionable
Not Optionable
Beta
0.86
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Pardeep Nijhawan FRCPC (Age 53)
    M.D., CEO, Company Secretary & Director
    Comp: $475.33k
  • Dr. Michael J. Brooks M.B.A. (Age 46)
    Ph.D., President
    Comp: $439.27k
  • Mr. Stephen L. Lemieux BA (Age 47)
    CPA, CA, CPA, MMPA, Chief Financial Officer
    Comp: $402.86k

EDSA Stock Analysis - Frequently Asked Questions

How have EDSA shares performed this year?

Edesa Biotech's stock was trading at $4.57 on January 1st, 2024. Since then, EDSA stock has increased by 18.6% and is now trading at $5.42.
View the best growth stocks for 2024 here
.

How were Edesa Biotech's earnings last quarter?

Edesa Biotech, Inc. (NASDAQ:EDSA) posted its earnings results on Friday, May, 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.11.

When did Edesa Biotech's stock split?

Edesa Biotech shares reverse split on the morning of Wednesday, October 11th 2023. The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

How do I buy shares of Edesa Biotech?

Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Edesa Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Edesa Biotech investors own include Pfizer (PFE), AbbVie (ABBV), VBI Vaccines (VBIV), Vaxart (VXRT), Exxon Mobil (XOM), Anavex Life Sciences (AVXL) and Occidental Petroleum (OXY).

This page (NASDAQ:EDSA) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners